These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9056597)

  • 21. The assessment of individual and population bioequivalence.
    Chinchilli VM
    J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of length of sampling schedule and washout interval on magnitude of drug carryover from period 1 to period 2 in two-period, two-treatment bioequivalence studies and its attendant effects on determination of bioequivalence.
    Dhariwal K; Jackson A
    Biopharm Drug Dispos; 2003 Jul; 24(5):219-28. PubMed ID: 12784322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence evaluation of two brands of metformin 500 mg tablets (Dialon & Glucophage)--in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2002 Oct; 23(7):301-6. PubMed ID: 12355581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-parametric assessment of non-inferiority with censored data.
    Freitag G; Lange S; Munk A
    Stat Med; 2006 Apr; 25(7):1201-17. PubMed ID: 16345041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Average bioequivalence of two oral formulations of fluconazole in healthy subjects after multiple dosing.
    Atanasova I; Bozhinova K; Terziivanov D
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):282-5. PubMed ID: 10395119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer simulations for bioequivalence trials: selection of analyte in BCS drugs with first-pass metabolism and two metabolic pathways.
    Navarro-Fontestad C; Gonzalez-Alvarez I; Fernández-Teruel C; Garcia-Arieta A; Bermejo M; Casabó VG
    Eur J Pharm Sci; 2010 Dec; 41(5):716-28. PubMed ID: 20932901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal sampling times in bioequivalence tests.
    Kong FH; Gonin R
    J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
    Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
    Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment.
    Tamimi JJ; Salem II; Mahmood Alam S; Zaman Q; Dham R
    Biopharm Drug Dispos; 2005 Jul; 26(5):205-10. PubMed ID: 15906418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative bioavailability between two Tramadol once-daily oral formulations.
    Hernandez-Lopez C; Martinez-Farnos L; Karhu D; Perez-Campos T; Rovira S; Encina G
    Methods Find Exp Clin Pharmacol; 2006; 28(6):373-8. PubMed ID: 16894407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose proportionality of once-daily trazodone extended-release caplets under fasting conditions.
    Karhu D; Groenewoud G; Potgieter MA; Mould DR
    J Clin Pharmacol; 2010 Dec; 50(12):1438-49. PubMed ID: 20173086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The subject-by-formulation interaction in multivariate bioequivalence.
    Cao L; Mathew T
    J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous confidence bands for nonlinear regression models with application to population pharmacokinetic analyses.
    Gsteiger S; Bretz F; Liu W
    J Biopharm Stat; 2011 Jul; 21(4):708-25. PubMed ID: 21516565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Approach to Testing for Average Bioequivalence Based on Modeling the Within-Period Dependence Structure.
    Chandrasekhar R; Shi Y; Hutson AD; Wilding GE
    J Biopharm Stat; 2015; 25(6):1320-38. PubMed ID: 25671781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Applying multilevel models in evaluation of bioequivalence (I)].
    Liu QL; Shen ZZ; Chen F; Li XS; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Robustness of bioequivalence procedures under Box-Cox alternatives.
    Xiao W; Barron AM; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):135-55. PubMed ID: 9056594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.